A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1

Sung Wook Park, Jennifer Nhieu, Shawna D. Persaud, Michelle C. Miller, Youlin Xia, Yi Wei Lin, Yu Lung Lin, Hiroyuki Kagechika, Kevin H. Mayo, Li Na Wei

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The rapidly accelerated fibrosarcoma (Raf) kinase is canonically activated by growth factors that regulate multiple cellular processes. In this kinase cascade Raf activation ultimately results in extracellular regulated kinase 1/2 (Erk1/2) activation, which requires Ras binding to the Ras binding domain (RBD) of Raf. We recently reported that all-trans retinoic acid (atRA) rapidly (within minutes) activates Erk1/2 to modulate cell cycle progression in stem cells, which is mediated by cellular retinoic acid binding protein 1 (Crabp1). But how atRA-bound Crabp1 regulated Erk1/2 activity remained unclear. We now report Raf kinase as the direct target of atRA-Crabp1. Molecularly, Crabp1 acts as a novel atRA-inducible scaffold protein for Raf/Mek/Erk in cells without growth factor stimulation. However, Crabp1 can also compete with Ras for direct interaction with the RBD of Raf, thereby negatively modulating growth factor-stimulated Raf activation, which can be enhanced by atRA binding to Crabp1. NMR heteronuclear single quantum coherence (HSQC) analyses reveal the 6-strand β-sheet face of Crabp1 as its Raf-interaction surface. We identify a new atRA-mimicking and Crabp1-selective compound, C3, that can also elicit such an activity. This study uncovers a new signal crosstalk between endocrine (atRA-Crabp1) and growth factor (Ras-Raf) pathways, providing evidence for atRA-Crabp1 as a novel modulator of cell growth. The study also suggests a new therapeutic strategy by employing Crabp1-selective compounds to dampen growth factor stimulation while circumventing RAR-mediated retinoid toxicity.

Original languageEnglish (US)
Article number10929
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Retinoic Acid Receptors
Fibrosarcoma
Tretinoin
Phosphotransferases
Intercellular Signaling Peptides and Proteins
Biomolecular Nuclear Magnetic Resonance
Retinoids
Cell Cycle
Stem Cells

PubMed: MeSH publication types

  • Journal Article

Cite this

A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1. / Wook Park, Sung; Nhieu, Jennifer; Persaud, Shawna D.; Miller, Michelle C.; Xia, Youlin; Lin, Yi Wei; Lin, Yu Lung; Kagechika, Hiroyuki; Mayo, Kevin H.; Wei, Li Na.

In: Scientific reports, Vol. 9, No. 1, 10929, 01.12.2019.

Research output: Contribution to journalArticle

Wook Park, Sung ; Nhieu, Jennifer ; Persaud, Shawna D. ; Miller, Michelle C. ; Xia, Youlin ; Lin, Yi Wei ; Lin, Yu Lung ; Kagechika, Hiroyuki ; Mayo, Kevin H. ; Wei, Li Na. / A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{409f487953024983b51bd35b7761fb0e,
title = "A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1",
abstract = "The rapidly accelerated fibrosarcoma (Raf) kinase is canonically activated by growth factors that regulate multiple cellular processes. In this kinase cascade Raf activation ultimately results in extracellular regulated kinase 1/2 (Erk1/2) activation, which requires Ras binding to the Ras binding domain (RBD) of Raf. We recently reported that all-trans retinoic acid (atRA) rapidly (within minutes) activates Erk1/2 to modulate cell cycle progression in stem cells, which is mediated by cellular retinoic acid binding protein 1 (Crabp1). But how atRA-bound Crabp1 regulated Erk1/2 activity remained unclear. We now report Raf kinase as the direct target of atRA-Crabp1. Molecularly, Crabp1 acts as a novel atRA-inducible scaffold protein for Raf/Mek/Erk in cells without growth factor stimulation. However, Crabp1 can also compete with Ras for direct interaction with the RBD of Raf, thereby negatively modulating growth factor-stimulated Raf activation, which can be enhanced by atRA binding to Crabp1. NMR heteronuclear single quantum coherence (HSQC) analyses reveal the 6-strand β-sheet face of Crabp1 as its Raf-interaction surface. We identify a new atRA-mimicking and Crabp1-selective compound, C3, that can also elicit such an activity. This study uncovers a new signal crosstalk between endocrine (atRA-Crabp1) and growth factor (Ras-Raf) pathways, providing evidence for atRA-Crabp1 as a novel modulator of cell growth. The study also suggests a new therapeutic strategy by employing Crabp1-selective compounds to dampen growth factor stimulation while circumventing RAR-mediated retinoid toxicity.",
author = "{Wook Park}, Sung and Jennifer Nhieu and Persaud, {Shawna D.} and Miller, {Michelle C.} and Youlin Xia and Lin, {Yi Wei} and Lin, {Yu Lung} and Hiroyuki Kagechika and Mayo, {Kevin H.} and Wei, {Li Na}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-47354-7",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1

AU - Wook Park, Sung

AU - Nhieu, Jennifer

AU - Persaud, Shawna D.

AU - Miller, Michelle C.

AU - Xia, Youlin

AU - Lin, Yi Wei

AU - Lin, Yu Lung

AU - Kagechika, Hiroyuki

AU - Mayo, Kevin H.

AU - Wei, Li Na

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The rapidly accelerated fibrosarcoma (Raf) kinase is canonically activated by growth factors that regulate multiple cellular processes. In this kinase cascade Raf activation ultimately results in extracellular regulated kinase 1/2 (Erk1/2) activation, which requires Ras binding to the Ras binding domain (RBD) of Raf. We recently reported that all-trans retinoic acid (atRA) rapidly (within minutes) activates Erk1/2 to modulate cell cycle progression in stem cells, which is mediated by cellular retinoic acid binding protein 1 (Crabp1). But how atRA-bound Crabp1 regulated Erk1/2 activity remained unclear. We now report Raf kinase as the direct target of atRA-Crabp1. Molecularly, Crabp1 acts as a novel atRA-inducible scaffold protein for Raf/Mek/Erk in cells without growth factor stimulation. However, Crabp1 can also compete with Ras for direct interaction with the RBD of Raf, thereby negatively modulating growth factor-stimulated Raf activation, which can be enhanced by atRA binding to Crabp1. NMR heteronuclear single quantum coherence (HSQC) analyses reveal the 6-strand β-sheet face of Crabp1 as its Raf-interaction surface. We identify a new atRA-mimicking and Crabp1-selective compound, C3, that can also elicit such an activity. This study uncovers a new signal crosstalk between endocrine (atRA-Crabp1) and growth factor (Ras-Raf) pathways, providing evidence for atRA-Crabp1 as a novel modulator of cell growth. The study also suggests a new therapeutic strategy by employing Crabp1-selective compounds to dampen growth factor stimulation while circumventing RAR-mediated retinoid toxicity.

AB - The rapidly accelerated fibrosarcoma (Raf) kinase is canonically activated by growth factors that regulate multiple cellular processes. In this kinase cascade Raf activation ultimately results in extracellular regulated kinase 1/2 (Erk1/2) activation, which requires Ras binding to the Ras binding domain (RBD) of Raf. We recently reported that all-trans retinoic acid (atRA) rapidly (within minutes) activates Erk1/2 to modulate cell cycle progression in stem cells, which is mediated by cellular retinoic acid binding protein 1 (Crabp1). But how atRA-bound Crabp1 regulated Erk1/2 activity remained unclear. We now report Raf kinase as the direct target of atRA-Crabp1. Molecularly, Crabp1 acts as a novel atRA-inducible scaffold protein for Raf/Mek/Erk in cells without growth factor stimulation. However, Crabp1 can also compete with Ras for direct interaction with the RBD of Raf, thereby negatively modulating growth factor-stimulated Raf activation, which can be enhanced by atRA binding to Crabp1. NMR heteronuclear single quantum coherence (HSQC) analyses reveal the 6-strand β-sheet face of Crabp1 as its Raf-interaction surface. We identify a new atRA-mimicking and Crabp1-selective compound, C3, that can also elicit such an activity. This study uncovers a new signal crosstalk between endocrine (atRA-Crabp1) and growth factor (Ras-Raf) pathways, providing evidence for atRA-Crabp1 as a novel modulator of cell growth. The study also suggests a new therapeutic strategy by employing Crabp1-selective compounds to dampen growth factor stimulation while circumventing RAR-mediated retinoid toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85069899604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069899604&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-47354-7

DO - 10.1038/s41598-019-47354-7

M3 - Article

C2 - 31358819

AN - SCOPUS:85069899604

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 10929

ER -